TL;DR
A focused medicinal chemistry effort was undertaken to design and synthesize a second-generation series of APJ antagonists with improved metabolic stability while retaining APJ antagonist activity, which significantly increased median survival and reduced metastatic tumor burden and ascites formation in an orthotopic ovarian cancer xenograft mouse model.
AI-generated by Semantic Scholar
